Can-Fite BioPharma Ltd. (CANF)
After hours:
| Previous Close | 1.3100 |
| Open | 1.2900 |
| Bid | 1.2800 x 2200 |
| Ask | 1.3000 x 1300 |
| Day's Range | 1.2600 - 1.3100 |
| 52 Week Range | 0.9400 - 4.3900 |
| Volume | |
| Avg. Volume | 3,891,498 |
| Market Cap | 37.204M |
| Beta (5Y Monthly) | 1.69 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6900 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 6.08 |
- Business Wire
Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro
PETACH TIKVA, Israel, January 13, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that pre-clinical studies with skin cells, modeling psoriasis in humans, show that Piclidenoson, the Company’s drug candidate for the treatment of psoriasis, destroys pathological skin cells. The Company’s scientists reported that in a cell culture
- Business Wire
Can-Fite to Conduct Investor Meetings during the J.P. Morgan Healthcare Conference
PETACH TIKVA, Israel, January 10, 2022--Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and liver diseases, announced today that it will hold one-on-one virtual investor meetings during the J.P. Morgan Healthcare Conference.
- Business Wire
Can-Fite Issues Letter to Shareholders
PETACH TIKVA, Israel, January 05, 2022--Can-Fite Issues Letter to Shareholders
